Analysis of MR images of mice in preclinical treatment monitoring of polycystic kidney disease.
A common cause of kidney failure is autosomal dominant polycystic kidney disease (ADPKD). It is characterized by the growth of cysts in the kidneys and hence the growth of the entire kidneys with eventual failure in most cases by age 50. No preventive treatment for this condition is available. Preclinical drug treatment studies use an in vivo mouse model of the condition. The analysis of mice imaging data for such studies typically requires extensive manual interaction, which is subjective and not reproducible. In this work both untreated and treated mice have been imaged with a high field, 9.4T, MRI animal scanner and a reliable algorithm for the automated segmentation of the mouse kidneys has been developed. The algorithm first detects the region of interest (ROI) in the image surrounding the kidneys. A parameterized geometric shape for a kidney is registered to the ROI of each kidney. The registered shapes are incorporated as priors to the graph cuts algorithm used to extract the kidneys. The accuracy of the automated segmentation has been demonstrated by comparing it with a manual segmentation. The processing results are also consistent with the literature for previous techniques.
Hadjidemetriou
Stathis
S
University Hospital Freiburg, Dept. of Diagnostic Radiology, Medical Physics, Hugstetter Street 55, 79106 Freiburg, Germany. efstathios.hadjidemetriou@uniklinik-freiburg.de
Reichardt
Wilfried
W
Buechert
Martin
M
Hennig
Juergen
J
von Elverfeldt
Dominik
D
D000818:Animals; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D007090:Image Interpretation, Computer-Assisted / Q000379:methods*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D051379:Mice; D009025:Morpholines / Q000627:therapeutic use*; D007690:Polycystic Kidney Diseases / Q000188:drug therapy* / Q000473:pathology*; D011379:Prognosis; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013141:Spiro Compounds / Q000627:therapeutic use*; D016896:Treatment Outcome
D009025:Morpholines; D013141:Spiro Compounds; C103281:satavaptan